Unicorn · Healthcare & Life Sciences

Temple doubles valuation to $375M in secondary sale

By Startup Enthusiast · 27 July 2026

What they do

Temple makes a forehead-worn wearable that tracks the body's metabolic state in real time

The company completed a secondary share sale at a $375M valuation, nearly double its seed round valuation of $190M

The deal included an ESOP buyback for about 20 employees, allowing them to sell up to 25% of vested options

Temple completed a secondary share sale at a $375M valuation, nearly double its previous $190M valuation.
The company also launched its first ESOP liquidity programme, allowing about 20 employees (out of 200-220 total) to sell up to 25% of vested ESOPs.
The ESOP buyback was done at the $375M valuation and was optional for eligible employees.
Founder Deepinder Goyal told employees that external investor interest exists at a ~$500M valuation for the next round, but the buyback was done at $375M to let employees benefit before the next raise.
Temple declined to comment on queries about the transaction.
The company is associated with Goyal's longevity research initiative Continue Research.
Nine startups have completed ESOP buybacks worth over $270M in 2026 so far.

The secondary sale nearly doubles Temple's valuation from its seed round in February 2026.
The ESOP buyback is the first for the company and signals confidence in its growth.
The transaction comes amid a broader trend of Indian startups offering liquidity to employees, with nine companies completing buybacks worth over $270M in 2026.

Temple is developing a forehead-worn wearable that measures the body's metabolic state in real time.
The device tracks a metric called 'Entropy', which represents metabolic and sympathetic demands on the body.
The product is currently in an early access programme, with a commercial launch expected within the next year, subject to validation.
Manufacturing partners include Ethereal Machines and Zetwerk.
The company has 200-220 employees and an ESOP pool of 10% of share capital.
Temple is associated with Deepinder Goyal's longevity research initiative Continue Research.
Continue Research published a hypothesis that reduced cerebral blood flow from gravity may be an overlooked aging factor, but Goyal said the wearable could succeed even if the hypothesis is wrong.

Commercial launch expected within the next year, subject to validation.
Next funding round anticipated at a valuation of ~$500M based on external investor interest.

Steadview Capital (existing) — Expected to hold ~5.3% stake after seed round.
Peak XV Partners (existing) — Expected to hold ~3.2% stake after seed round.
Vy Capital (existing) — Participated in seed round.
Info Edge (existing) — Participated in seed round.
Dharana Capital (existing) — Participated in seed round.
NKSquared (existing) — Family office of Zerodha co-founder Nikhil Kamath, participated in seed round.

Product: A brain-monitoring wearable device designed to track health metrics.
Customers: Individual consumers interested in health and brain-monitoring technology.
How it makes money: Direct sale of wearable hardware devices to consumers.
What sets it apart: Claims to be the smallest wearable device on the market.
Operations: Manufacturing is outsourced to partners like Zetwerk and Ethereal Machines.